441055-14-7Relevant articles and documents
CALCIUM CHANNEL AGONISTS
-
Page/Page column 26, (2014/12/12)
Embodiments of calcium channel agonists, as well as methods of making and using the calcium channel agonists, are disclosed. The disclosed calcium channel agonists and corresponding salt forms have a structure according to general formula I wherein each bond depicted as " " is a single bond or a double bond as needed to satisfy valence requirements; Z1, Z2, Z3, Z4, and Z5 independently are nitrogen or carbon; R1 and R3 are alkyl; R2 is alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and R4 is alkyl or hydroxyalkyl.
Biaryl purine derivatives as potent antiproliferative agents: Inhibitors of cyclin dependent kinases. Part I
Trova, Michael P.,Barnes, Keith D.,Barford, Curt,Benanti, Travis,Bielaska, Mark,Burry, Lori,Lehman, John M.,Murphy, Christine,O'Grady, Harold,Peace, Denise,Salamone, Susan,Smith, Jennifer,Snider, Patricia,Toporowski, Joseph,Tregay, Steven,Wilson, Alison,Wyle, Michael,Zheng, Xiaozhang,Friedrich, Thomas D.
scheme or table, p. 6608 - 6612 (2010/06/12)
The introduction of an aryl ring onto the 4-position of the C-6 benzyl amino group of the Cdk inhibitor roscovitine (2), maintained the potent Cdk inhibition demonstrated by roscovitine (2) as well as greatly improving the antiproliferative activity. A series of C-6 biarylmethylamino derivatives was prepared addressing modifications on the C-6 biaryl rings, N-9 and C-2 positions to provide compounds that displayed potent cytotoxic activity against tumor cell lines. In particular, derivative 21h demonstrated a >750-fold improvement in the growth inhibition of HeLa cells compared to roscovitine (2).
